TrialHuman vaccines & immunotherapeutics2019

A phase III clinical trial to evaluate the safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine (PPV23) in healthy children, adults, and elderly.

Lili Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.